Estrella Immunopharma, Inc. ESLA
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -22.60% | 28.48% | -42.24% | 17.76% | 108.22% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -62.41% | 8.92% | -41.61% | 42.18% | 40.38% |
| Operating Income | 62.41% | -8.92% | 41.61% | -42.18% | -40.38% |
| Income Before Tax | 58.40% | -8.92% | 41.61% | -42.18% | -40.38% |
| Income Tax Expenses | -- | -- | -100.00% | -- | -43.75% |
| Earnings from Continuing Operations | 58.41% | -8.92% | 41.62% | -42.18% | -40.34% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 58.41% | -8.92% | 41.62% | -42.18% | -40.34% |
| EBIT | 62.41% | -8.92% | 41.61% | -42.18% | -40.38% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 65.04% | 6.37% | 43.94% | -38.69% | -41.68% |
| Normalized Basic EPS | 65.03% | 6.34% | 44.20% | -38.77% | -41.72% |
| EPS Diluted | 65.04% | 6.37% | 43.94% | -38.69% | -41.68% |
| Normalized Diluted EPS | 65.03% | 6.34% | 44.20% | -38.77% | -41.72% |
| Average Basic Shares Outstanding | 18.89% | 16.39% | 4.03% | 2.45% | -0.98% |
| Average Diluted Shares Outstanding | 18.89% | 16.39% | 4.03% | 2.45% | -0.98% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |